Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00082972" target="_blank" >RIV/65269705:_____/25:00082972 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00142837
Result on the web
<a href="https://link.springer.com/article/10.1007/s00277-025-06703-5" target="_blank" >https://link.springer.com/article/10.1007/s00277-025-06703-5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00277-025-06703-5" target="_blank" >10.1007/s00277-025-06703-5</a>
Alternative languages
Result language
angličtina
Original language name
Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia
Original language description
Randomized clinical trials (RCTs) are the cornerstone of evidence-based medicine. Their findings shape everyday clinical practice by guiding the development and use of new therapeutic agents, improving patient outcomes, and forming the basis of evidence-based clinical guidelines. To ensure that these findings are robust and reliable, strict adherence to study protocols is essential. During the screening process, patients must meet all inclusion criteria and none of the exclusion criteria. This methodology helps to protect vulnerable populations-such as those with significant comorbidities or on concomitant medication-and ensures data consistency and validity. However, such stringent selection criteria may exclude many patients typically seen in daily practice, resulting in underrepresentation of real-world populations, and risk introducing inadequate generalizability of the trial results.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of Hematology
ISSN
0939-5555
e-ISSN
1432-0584
Volume of the periodical
104
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
6105-6108
UT code for WoS article
001608353100001
EID of the result in the Scopus database
2-s2.0-105020886322